RP-A501 for cardiomyopathy, hypertrophic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 5 Sep 2023: Trial started, NCT06092034
  2. 23 Oct 2023: Trial registered, NCT06092034

The trials

NCT03882437: Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

State
Completed
Phase
Phase 1
People
7 taking part
Started
17 Apr 2019
Primary completion
3 Jul 2025
Arms
RP-A501
Results
None posted
  1. 20 Mar 2019: Trial registered
  2. 17 Apr 2019: Trial started
  3. 3 Jul 2025: Trial completed

NCT06092034: A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

State
Under way
Phase
Phase 2
People
18 planned
Started
5 Sep 2023
Primary completion
Jun 2028
Arms
RP-A501
Results
None posted
  1. 5 Sep 2023: Trial started
  2. 23 Oct 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.